OTCMKTS:ZYXI Zynex Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.90 +0.20 (+1.20 %) (As of 09/28/2020 12:00 AM ET) Add Compare Share Today's Range$16.30Now: $16.90▼$17.1750-Day Range$14.28MA: $16.06▼$18.0952-Week Range$7.51Now: $16.90▼$29.73Volume390,394 shsAverage Volume788,322 shsMarket Capitalization$586.53 millionP/E Ratio76.82Dividend YieldN/ABeta1.05 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.38, Zynex has a forecasted upside of 56.1% from its current price of $16.90.Amount of Analyst CoverageZynex has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesZynex has received 187 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZynex has received 150 “underperform” votes. (Add your “underperform” vote.)Community SentimentZynex has received 55.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote “Outperform” if you believe ZYXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have sold 55,461.17% more of their company's stock than they have bought. Specifically, they have bought $49,495.00 in company stock and sold $27,500,000.00 in company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Zynex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 17.86% in the coming year, from $0.28 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 76.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 76.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.97.Price to Book Value per Share RatioZynex has a P/B Ratio of 112.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ZYXI Previous Symbol CUSIPN/A CIK846475 Webwww.zynexmed.com Phone303-703-4906Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.23Price-To-Earnings Trailing P/E Ratio76.82 Forward P/E Ratio60.36 P/E GrowthN/A Sales & Book Value Annual Sales$23.43 million Price / Sales25.03 Cash Flow$0.94 per share Price / Cash Flow17.91 Book Value$0.15 per share Price / Book112.67Profitability EPS (Most Recent Fiscal Year)$0.22 Net Income$7.36 million Net Margins33.33% Return on Equity152.81% Return on Assets95.46%Miscellaneous EmployeesN/A Outstanding Shares34,706,000Market Cap$586.53 million Next Earnings DateN/A OptionableNot Optionable $16.90 +0.20 (+1.20 %) (As of 09/28/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ZYXI News and Ratings via Email Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. Zynex (OTCMKTS:ZYXI) Frequently Asked Questions How has Zynex's stock been impacted by Coronavirus (COVID-19)? Zynex's stock was trading at $11.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZYXI stock has increased by 52.4% and is now trading at $16.90. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Zynex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynex. How were Zynex's earnings last quarter? Zynex Inc. (OTCMKTS:ZYXI) posted its quarterly earnings results on Tuesday, July, 28th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.09 by $0.00. The business earned $19.26 million during the quarter, compared to analysts' expectations of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's earnings history. What guidance has Zynex issued on next quarter's earnings? Zynex issued an update on its FY 2020 IntraDay earnings guidance on Thursday, September, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80-85 million, compared to the consensus revenue estimate of $83.65 million. What price target have analysts set for ZYXI? 4 brokerages have issued 1-year price targets for Zynex's stock. Their forecasts range from $22.50 to $30.00. On average, they anticipate Zynex's stock price to reach $26.38 in the next twelve months. This suggests a possible upside of 56.1% from the stock's current price. View analysts' price targets for Zynex. Who are some of Zynex's key competitors? Some companies that are related to Zynex include CONMED (CNMD), CONMED (CNMD), LivaNova (LIVN), InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), Viewray (VRAY), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Cutera (CUTR), Stereotaxis (STXS), Soleno Therapeutics (SLNO), BioSig Technologies (BSGM) and Fonar (FONR). View all competitors. What other stocks do shareholders of Zynex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Advanced Micro Devices (AMD), Pfizer (PFE), AbbVie (ABBV), Activision Blizzard (ATVI), Chromadex (CDXC), FuelCell Energy (FCEL), Farfetch (FTCH), K12 (LRN), AT&T (T) and Big Lots (BIG). Who are Zynex's key executives? Zynex's management team includes the following people: Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)Mr. David B. Mogill, VP of OperationsMr. Robert Bird, VP of MarketingMr. Steve Siefring, Director of Bus. Devel. What is Zynex's stock symbol? Zynex trades on the OTCMKTS under the ticker symbol "ZYXI." Who are Zynex's major shareholders? Zynex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.22%), Federated Hermes Inc. (0.93%), Russell Investments Group Ltd. (0.67%), Bank of New York Mellon Corp (0.50%), Principal Financial Group Inc. (0.33%) and Principal Financial Group Inc. (0.33%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends for Zynex. Which institutional investors are selling Zynex stock? ZYXI stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, Cadence Capital Management LLC, AQR Capital Management LLC, WINTON GROUP Ltd, and Bridgeway Capital Management Inc.. View insider buying and selling activity for Zynex. Which institutional investors are buying Zynex stock? ZYXI stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Vanguard Group Inc., Principal Financial Group Inc., Principal Financial Group Inc., Bank of New York Mellon Corp, Genesee Capital Advisors LLC, Mackay Shields LLC, and Mutual of America Capital Management LLC. View insider buying and selling activity for Zynex. How do I buy shares of Zynex? Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zynex's stock price today? One share of ZYXI stock can currently be purchased for approximately $16.90. How big of a company is Zynex? Zynex has a market capitalization of $586.53 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. What is Zynex's official website? The official website for Zynex is www.zynexmed.com. How can I contact Zynex? Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
